VivoSeq
Neurology

Optic Neuritis

31

Pipeline Programs↗

5

Active Trials↗

21

Companies Involved↗

Optic Neuritis is a moderately active landscape with 31 programs across 21 companies. The most active players are Acorda Therapeutics, NovaMed Pharmaceuticals Inc., EMD Serono. 4 therapies are approved with 11 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

65/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Acorda Therapeutics

1 program

Phase 1N

NovaMed Pharmaceuticals Inc.

1 program

Phase 1EMD Serono logo

EMD Serono

1 program

Phase 2H

Hyundai Pharmaceutical Co., LTD.

1 program

Phase 2V

Viatris Specialty LLC

1 program

Phase 2Argenx logo

Argenx

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

94%

Small molecule

33 of 35 classified programs — the dominant modality here.

6%ALL OTHERSMonoclonal antibody13%Protein / enzyme13%

Small molecule leads; the ring shows all 35 classified programs, each share of the total. Modality classified for 95% of 39 pipeline programs.

Analysis

Trial Status

32

clinical trials

Completed13 · 41%
Unknown status7 · 22%
Terminated7 · 22%
Recruiting5 · 16%

Clinical Trials

Trial Activity

32 trials

Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
Recruiting·UUniversity of California, San Francisco·Phase 2·NCT02521311·90 enrolled
Efgartigimod for the Treatment of Acute Optic Neuritis
Recruiting·—·Phase 2·NCT06453694·20 enrolled
Edaravone in the Treatment of Optic Neuritis
Recruiting·FFirst Affiliated Hospital of Guangxi Medical University·N/A·NCT05540262·50 enrolled
A Randomized Controlled, Open-Label, Rater-Blinded Pragmatic Trial, Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX)
Recruiting·MMayo Clinic·Phase 3·NCT07100990·382 enrolled
A Randomized, Double-masked, Placebo-controlled Study Assessing the Efficacy and Safety of Privosegtor (OCS-05) in Patients With Optic Neuritis (ON)
Recruiting·OOculis·Phase 3·NCT07623668·210 enrolled
Optic Neuritis Recovery After Oral or IV Corticosteroids
Completed·LLondon Health Sciences Centre·Phase 2/3·NCT01524250·51 enrolled
Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis
Completed·NNeuro-Ophthalmologic Associates, PC·Phase 1·NCT01987167·25 enrolled
OCS-05 in Patients With Optic Neuritis
Completed·OOculis·Phase 2·NCT04762017·36 enrolled
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)
Completed·Teva logoTeva·Phase 3·NCT00856635·44 enrolled
BIIB033 In Acute Optic Neuritis (AON)
Completed·Biogen logoBiogen·Phase 2·NCT01721161·82 enrolled
Intravenous Immunoglobulin Therapy in Optic Neuritis
Completed·National Eye Institute (NEI)·Phase 3·NCT00000117
Amiloride Clinical Trial In Optic Neuritis
Completed·UUniversity of Oxford·Phase 2·NCT01802489·46 enrolled
Neuroprotection With Phenytoin in Optic Neuritis
Completed·UUniversity College, London·Phase 2·NCT01451593·92 enrolled
Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis
Completed·TTehran University of Medical Sciences·Phase 2·NCT02939937·71 enrolled
TLR-9 Antagonism in Steroid Resistant Optic Neuritis
Completed·SSudhalkar Eye Hospital·N/A·NCT01424735·8 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)